Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song

Blood (2023) 142 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2023-186788

Published: 2023

Journal Articles

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4442.

https://doi.org/10.1182/blood-2023-186800

Published: 2023

Journal Articles

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Ranjana H. Advani, Abraham Avigdor, Anna Maria Sureda Balari, David Lavie, Stefan Hohaus, Jan M. Zaucha, Vu Minh Hua, Vittorio Ruggero Zilioli, Raimundo Gazitua, Muhit Ozcan, Amos Odeleye-Ajakaye, Nishitha Reddy, Patricia Marinello, Jane N. Winter

Blood (2023) 142 (Supplement 1): 3068.

https://doi.org/10.1182/blood-2023-181171

Published: 2023

Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 4440.

https://doi.org/10.1182/blood-2023-182019

Published: 2023

Journal Articles

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Armando Santoro, Nathalie A. Johnson, Kerry J. Savage, Abraham Avigdor, Ali Bazargan, Peter Borchmann, Robin Gasiorowski, Gareth P. Gregory, Yair Herishanu, Sumit Madan, Leonard Minuk, Gerardo Musuraca, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 1725.

https://doi.org/10.1182/blood-2023-182536

Published: 2023

Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

Blood (2023) 142 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2023-186719

Published: 2023

Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman

Blood (2023) 142 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2023-182128

Published: 2023

Journal Articles

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie, John Timmerman, Ramón García-Sanz, Won Seog Kim, Tae Min Kim, Abraham Avigdor, Daan Dierickx, Deepa Jagadeesh, Daniel L. Molin, Muhit Ozcan, Omur Gokmen Sevindik, Hayder Saeed, Yulia Sidi, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2023-182119

Published: 2023

Journal Articles

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz

Blood (2023) 142 (10): 878–886.

https://doi.org/10.1182/blood.2022019386

Published: 2023

Includes: Supplemental data

Journal Articles

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, A. Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

Blood (2023) 142 (2): 141–145.

https://doi.org/10.1182/blood.2022019340

Published: 2023

Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon

Blood (2021) 138 (Supplement 1): 528.

https://doi.org/10.1182/blood-2021-148607

Published: 2021

Journal Articles

Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Pier Luigi Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Waleswski, Alejandro Majlis, Laura Fogliatto, Alejandro Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Gilles Salles, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

Blood (2021) 138 (Supplement 1): 306.

https://doi.org/10.1182/blood-2021-148082

Published: 2021

Journal Articles

Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study

Rushdia Yusuf, Thomas Jemielita, Patricia Marinello

Blood (2021) 138 (Supplement 1): 2484.

https://doi.org/10.1182/blood-2021-151728

Published: 2021

Journal Articles

Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy

Philippe Armand, John Kuruvilla, Alex F. Herrera, Vincent Ribrag, Pauline Brice, Catherine Thieblemont, Bastian Von Tresckow, Eunhee Kim, Robert Orlowski, Samhita Chakraborty, Patricia Marinello, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 3924.

https://doi.org/10.1182/blood-2021-148528

Published: 2021

Journal Articles

Pembrolizumab and Chemotherapy As First-Line Treatment of Patients with Newly Diagnosed Early Unfavorable or Advanced-Stage Classical Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Jane N. Winter, Akash Nahar, Eunhee Kim, Patricia Marinello

Blood (2021) 138 (Supplement 1): 1379.

https://doi.org/10.1182/blood-2021-147276

Published: 2021

Journal Articles

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Philippe Armand, Pier Luigi Luigi Zinzani, Hun Ju Lee, Nathalie Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz

Blood (2021) 138 (Supplement 1): 1366.

https://doi.org/10.1182/blood-2021-147881

Published: 2021

Journal Articles

Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study

Pier Luigi Zinzani, MD, Vladimir Melnichenko, Krimo Bouabdallah, MD, Jan Walewski, MD PhD, Alejandro Majlis, MD, Laura Fogliatto, MDPhD, Dolores Caballero, MD PhD, Beth A. Christian, MD, Zafer Gulbas, MD, Muhit Özcan, MD, Gilles Salles, MD PhD, Margaret A. Shipp, MD, Seth Thompson, Robert J Orlowski, MD, Patricia Marinello, Philippe Armand, MD PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-137080

Published: 2020

Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142565

Published: 2020

Journal Articles

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie Johnson, MD, Pauline Brice, John Radford, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, MD PhD, Bastian Von Tresckow, Margaret A. Shipp, MD, Alex F. Herrera, MD, Jianxin Lin, Eunhee Kim, Mohammed Farooqui, Patricia Marinello, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 240.

https://doi.org/10.1182/blood-2019-127280

Published: 2019

Journal Articles

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Philippe Armand, Pier Luigi Luigi Zinzani, MD, John Palcza, Jane Anne Healy, Akash Nahar, Patricia Marinello, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1548.

https://doi.org/10.1182/blood-2019-127474

Published: 2019

NARROW

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study

Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy

Pembrolizumab and Chemotherapy As First-Line Treatment of Patients with Newly Diagnosed Early Unfavorable or Advanced-Stage Classical Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only